Global Non-Hodgkin Lymphoma Market - 2023-2030

Global Non-Hodgkin Lymphoma Market - 2023-2030

The Global Non-Hodgkin Lymphoma Market reached US$ 7.3 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 13.5 billion by 2030. The global non-Hodgkin lymphoma market is expected to exhibit a CAGR of 8.2% during the forecast period (2023-2030).

The NHL market has witnessed a notable emphasis on the development and commercialization of targeted therapies. Biomarker identification and utilization have gained traction in NHL while generating real-world evidence has become increasingly important in assessing treatment effectiveness and value. These trends collectively shape the evolving landscape of NHL treatment, with a focus on personalized approaches, improved outcomes, and enhancing the patient experience throughout their treatment journey.

Furthermore, the NHL market is driven by the development of innovative treatment approaches, extensive research and development efforts to understand NHL biology, and supportive government policies that aim to enhance access to healthcare services and provide favorable reimbursement systems.

Market Dynamics

The Increasing FDA Approvals are Expected to Drive Global Non-Hodgkin Lymphoma Market

Genentech, a member of the Roche Group, announced on July 5, 2022, that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) and granted Priority Review for mosunetuzumab. This potential first-in-class CD20xCD3 T-cell engaging bispecific antibody is being evaluated for the treatment of adults with relapsed or refractory follicular lymphoma (FL) who have undergone at least two prior systemic therapies.

FL is the most common indolent form of non-Hodgkin's lymphoma (NHL), characterized by slow growth and frequent recurrence after initial treatment. The FDA is expected to decide on the approval of mosunetuzumab, a novel cancer immunotherapy, by December 29, 2022.

Similarly, on December 22, 2022, Kite Pharma, Inc., a Gilead Company and Daiichi Sankyo Co., Ltd, jointly announced that the Japan Ministry of Health, Labour and Welfare (MHLW) approved Yescarta (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, for the initial treatment of patients with relapsed/refractory large B-cell lymphoma ( R/R LBCL): diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, transformed follicular lymphoma, and high-grade B-cell lymphoma.

Yescarta should be used only in patients who have not received a prior transfusion of CAR T-cells targeted at the CD19 antigen. Therefore, the increasing FDA approvals are expected to drive the global non-Hodgkin lymphoma market.

Advancing Research in Treating Non-Hodgkin Lymphoma and Predicting the Risk of Early Disease Progression is Expected to Drive Global Non-Hodgkin Lymphoma Market

According to the American Society of Clinical Oncology (ASCO) Article, published on January 25, 2023, during the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition, which took place from December 10 to 13 in New Orleans, Louisiana, significant research findings in the field of non-Hodgkin lymphoma were presented.

Additionally, two studies focused on predicting early disease progression in lymphoma patients. The first study introduced the FLIPI24 model, which utilized factors such as age, hemoglobin levels, white blood cell count, lactate dehydrogenase levels, and beta-2-microglobulin levels to identify follicular lymphoma patients at risk for early disease progression.

The second study utilized the CCP-32 predictor, a genomic-based model, to identify diffuse large B-cell lymphoma patients who may be at risk for early disease progression. These research findings presented at the ASH Annual Meeting provide valuable insights into new treatment approaches for non-Hodgkin lymphoma and predictive models that aid in identifying patients at risk for early disease progression. Thus, owing to the above factors, the market is expected to drive over the forecast period.

Significant Challenges Possessed with Drug Resistance in NHL Expected to Hamper Global Non-Hodgkin Lymphoma Market

Drug resistance in Non-Hodgkin Lymphoma (NHL) occurs when the cancer cells adapt and become resistant to the effects of a particular treatment. This resistance can result from various mechanisms, including genetic mutations, alterations in drug targets, activation of alternative signaling pathways, or enhanced DNA repair mechanisms. Drug resistance poses a significant challenge in managing NHL, as it can lead to treatment failure, disease progression, and limited treatment options for patients.

An example of drug resistance in NHL is observed in patients receiving chemotherapy, specifically, the class of drugs called anthracyclines. Anthracyclines are commonly used in the treatment of NHL, including Diffuse Large B-cell Lymphoma (DLBCL). However, some DLBCL patients may develop resistance to anthracyclines, leading to treatment failure and a poorer prognosis.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the Non-Hodgkin Lymphoma (NHL) market. During the height of the pandemic, many healthcare systems were overwhelmed, and non-urgent medical procedures and screenings were postponed or canceled. This led to delays in the diagnosis of NHL and initiation of treatment for patients. As a result, some NHL cases have been diagnosed at later stages, potentially affecting treatment outcomes.

Clinical trials are vital for developing new treatments and improving outcomes in NHL. However, the pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new therapies.

Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. This diversion of resources and attention may have temporarily impacted the progress of NHL-related research and development activities.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict has had significant implications for various aspects of life in both countries, including healthcare and the management of diseases such as non-Hodgkin lymphoma (NHL). The conflict has led to the destruction and disruption of healthcare infrastructure in affected regions. Medical facilities, including hospitals and clinics, were damaged or inaccessible, making it challenging for patients with NHL to receive proper diagnosis, treatment, and follow-up care.

The conflict resulted in limited availability of medical resources, including diagnostic equipment, medications, and specialized healthcare professionals. This scarcity may lead to delays in diagnosis, inadequate treatment options, and suboptimal disease management for NHL patients.

The conflict has resulted in population displacement, with people forced to leave their homes and seek refuge in safer areas. This displacement can disrupt patients' continuity of care, as they may have difficulty accessing their regular healthcare providers and treatment facilities, potentially leading to interruptions in their NHL treatment.

Segment Analysis

The global non-Hodgkin lymphoma market is segmented based on disease type, drug class, route of administration, distribution channel, and region.

CAR T-Cell Therapy from the Drug Class Segment Accounts for 20.5% of the Market Share Owing to the Rapidly Evolving Treatment Approach, and Increasing Clinical Trials

CAR T-cell therapy has emerged as a highly promising and rapidly evolving treatment approach for certain types of Non-Hodgkin Lymphoma (NHL). CAR T-cell therapy involves genetically modifying a patient's T cells to express chimeric antigen receptors (CARs) that specifically target cancer cells. These engineered T cells are then infused back into the patient, where they recognize and destroy cancer cells.

CAR T-cell therapy has shown remarkable efficacy in the treatment of B-cell malignancies, including certain subtypes of NHL, such as Diffuse Large B-cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). For example, the CAR T-cell therapy products axicabtagene ciloleucel (Yescarta) and tisagenlecleucel (Kymriah) have been approved by regulatory authorities for the treatment of relapsed or refractory DLBCL and FL.

The adoption of CAR T-cell therapy has rapidly increased due to its impressive clinical outcomes, including high response rates and durable remissions in patients who have failed other treatments. However, it is important to note that CAR T-cell therapy is currently approved for specific indications and is not suitable for all NHL patients. It is primarily used in cases where other treatment options have been exhausted or have failed.

Furthermore, in 2022, an interventional trial with the identifier ML43165 was conducted by Lazaros Lekakis. The trial is a single-arm Phase 2 study that aims to evaluate the efficacy of an FDA-approved anti-CD19 CAR-T therapy followed by consolidation treatment with mosunetuzumab and polatuzumab in patients with refractory or relapsed aggressive Non-Hodgkin Lymphoma (NHL). The estimated completion date for this study is December 2027. Thus, owing to the above factors, the market segment is expected to hold the largest market share over the forecast period.

Geographical Analysis

North America Accounted for Approximately 41.9% of the Market Share Owing to the Rising incidences of NHL and Several Therapy Approvals

The increasing incidences of NHL, several therapy approvals, the growing awareness of the disease, and increasing clinical trials are expected to drive the North American region over the forecast period.

For instance, on April 19, 2023, the U.S. Food and Drug Administration (FDA) announced it has approved elotuzumab vedotin-piiq (Polivy, Genentech, Inc.) with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater.

Similarly, on April 1, 2022, the Food and Drug Administration approved axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) for adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy. It is not indicated for the treatment of patients with primary central nervous system lymphoma.

Competitive Landscape

The major global players in the market include AbbVie, Inc. (Pharmacyclics LLC), AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company (Celgene Corp.), Gilead Sciences, Inc. (Kite Pharma), Johnson & Johnson (Janssen Biotech, Inc.), Merck & Co., Inc., Novartis AG, Roche Holding AG (F. Hoffmann-La Roche AG), Seagen, Inc. (Seattle Genetics, Inc.), Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd. among others.

Why Purchase the Report?
• To visualize the global non-Hodgkin lymphoma market segmentation based on the disease type, drug class, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of non-Hodgkin lymphoma market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global non-Hodgkin lymphoma market report would provide approximately 69 tables, 70 figures, and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies